XHKG
2211
Market cap19mUSD
Dec 05, Last price
1.93HKD
1D
1.05%
1Q
28.67%
Jan 2017
-45.63%
IPO
-92.49%
Name
Universal Health International Group Holding Ltd
Chart & Performance
P/E
340.00
P/S
0.13
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
16.64%
Rev. gr., 5y
-17.12%
Revenues
1.09b
-25.46%
Net income
413k
P
CFO
-102m
L+424.29%
Dividend
Sep 17, 20150.015 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Universal Health International Group Holding Limited, an investment holding company, engages in the distribution, wholesale, and retail of drugs, healthcare products, and other pharmaceutical products in the northeastern region of the People's Republic of China. Its product categories include Chinese patent medicines, chemical preparations, antibiotics and biochemical drugs, traditional Chinese medicine decoction pieces, biological products, protein assimilation preparations, peptide hormones, blood products, disinfection products, medical equipment, prepackaged foods, nutritional foods, health care products, stereotyped packaging cosmetics, and daily necessities, as well as family planning supplies, such as contraceptives and utensils; dairy products comprise infant formula milk powder; etc. The company also provides storage services. It serves pharmaceutical retailers, hospitals, clinics, and distributors. The company was formerly known as Jintian Pharmaceutical Group Limited and changed its name to Universal Health International Group Holding Limited in July 2015. Universal Health International Group Holding Limited was founded in 1998 and is headquartered in Shenyang, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||